Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

NCT07590986 | Recruiting

• 1 other identifier: MPN-TCR
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are:

• Are there T cells in the bone marrow that can recognize MPN cells?
• Which targets (antigens) on MPN cells are recognized by these immune cells?
• Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will:
• Allow researchers to study immune cells and genetic material from these samples
• Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.

Conditions

Primary Myelofibrosis (PMF); Polycytemia Vera; Myeloproliferative Neoplasm (MPN); Essential Thrombocythemia (ET)

Outcome Measures

Primary Outcomes (1)

• Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens

  Throughout the whole study, approximately during 10 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

(i) Adult patients previously diagnosed with or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. (ii) Healthy controls undergoing hip replacement surgery, that have not been diagnosed with any hematological disease.

You may qualify if:

• Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.
• Patients not previously diagnosed with a haematological disease as controls

You may not qualify if:

• Patients with any other hematological malignancy.

Sponsors & Collaborators

• Université Catholique de Louvain: lead

Study Sites (1)

de Duve Institute, UCLouvain

Brussels, Woluwe, 1200, Belgium

RECRUITING

MeSH Terms

Conditions

Myeloproliferative Disorders; Thrombocythemia, Essential; Primary Myelofibrosis

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Blood Coagulation Disorders; Thrombocytosis; Blood Platelet Disorders; Hemorrhagic Disorders

Central Study Contacts

Sophie Lucas

CONTACT

0032 (0)2 436 23 00; sophie.lucas@uclouvain.be

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2026
• First Posted: May 15, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): December 1, 2036
• Study Completion (Estimated): January 1, 2037
• Last Updated: May 15, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)